Shopping Cart
- Remove All
- Your shopping cart is currently empty
VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $31 | In Stock | |
10 mg | $56 | In Stock | |
25 mg | $98 | In Stock | |
50 mg | $139 | In Stock | |
100 mg | $198 | In Stock | |
200 mg | $297 | In Stock | |
1 mL x 10 mM (in DMSO) | $35 | In Stock |
Description | VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor. |
Targets&IC50 | PI3Kδ:2.7 nM, PI3Kβ:21 nM, PI3Kα:2.6 nM, PI3Kγ:3.0 nM, mTOR:3.4 nM |
In vitro | VS-5584 is an ATP-competitive inhibitor which selectively inhibits PI3K/mTOR signaling with equivalent low nanomolar potency against all human Class I PI3K isoforms and mTOR kinase. VS-5584 is approximately 10-fold selective for cancer stem cells with an EC50 of 15 nM in HMLE breast cancer cells. VS-5584 preferentially decreases CD44Hi/CD24Lo cells in an HMLER immortalized mammary cancer cell line. In SUM159 cells, VS-5584 effectively eliminates the cancer stem cell side population. [1] A large human cancer cell line panel screen (436 lines) reveals broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment. In the FLT3-ITD harboring MV4-11 cells, VS-5584 blocks pAkt (S473) and pAkt (T308) with IC50 of 12 and 13 nM, respectively. The IC50 of VS-5584 for pS6 (S240/244), pAkt (S473), and pAkt (T308) are 20, 23, and 15 nM, respectively. [2] |
In vivo | In mice bearing triple negative breast cancer tumors, oral dosing of VS-5584 decreases tumor cancer stem cells and induces tumor regression in taxane-resistant models. [1] In a PTENnull human prostate PC3 xenograft model, treatment with VS-5584 leads to significant tumor growth inhibition (TGI) of 79% and 113% for 11 and 25 mg/kg, respectively. In a FLT3-ITD AML xenograft model, VS-5584 treatment induces dose-dependent inhibition of tumor growth (28% for 3.7 mg/kg and 76% for 11 mg/kg). [2] |
Kinase Assay | In vitro mTOR kinase assays : The reaction mixture consisted of the following components in 10 μL assay buffer (50 mM Hepes pH 7.5, 10 mM MgCl 2, 3 mM MnCl 2, 1 mM EGTA, 2 mM DTT, 0.01%Tween-20): 0.10 μg/mL of in-house generated mTOR enzyme, 0.05 μM ULight-eIF4E-binding protein 1 (Thr37/46) peptide and 10 μM ATP. The mixture is incubated for 60 min at room temperature. 10 μL of Detection mixture consisted of 16 mM EDTA, 0.004 mM Eu-W1024-labeled Anti-Phospho-eIF4E-binding protein 1-(Thr37/46) antibody and 1X LANCE? Detection Buffer is then added and incubated for 60 min. |
Cell Research | CellTiter-Glo assay(Only for Reference) |
Alias | VS5584, VS 5584, SB2343 |
Molecular Weight | 354.41 |
Formula | C17H22N8O |
Cas No. | 1246560-33-7 |
Smiles | CC(C)n1c(C)nc2c(nc(nc12)N1CCOCC1)-c1cnc(N)nc1 |
Relative Density. | 1.48 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 3 mg/mL (8.46 mM) DMSO: 66 mg/mL (186.2 mM) H2O: < 1 mg/mL (insoluble or slightly soluble) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.